Krystal Biotech, Inc. (KRYS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Krystal Biotech reported revenue of $389.1M, up 33.9% from $290.5M the year before. Net income was $204.8M (a 52.6% net margin), or $6.84 per diluted share. Operating margin was 41.5%. Operating activities generated $200.9M of cash, leaving $188.9M of free cash flow. At fiscal year end, Krystal Biotech held $1.33B in total assets against $114.2M in total liabilities, including $496.3M of cash and equivalents.
Open the full interactive Krystal Biotech financials → Quarterly statements, key ratios, valuation history and price charts.
Krystal Biotech Key Stats
| Share Price | $321.16 |
|---|---|
| Market Cap | $9.85B |
| P/E Ratio | 47.0 |
| Revenue YoY Growth | +33.9% |
| 52-Week Range | $184.74 – $378.15 |
| Shares Outstanding | 29.5 million (basic, 2026 Q2) |
Krystal Biotech Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $50.7M | $290.5M | $389.1M |
| Operating Income | -$33.0M | -$68.3M | -$145.2M | -$109.7M | $65.7M | $161.3M |
| Pre-Tax Income | -$32.2M | -$69.6M | -$140.0M | $12.9M | $95.4M | $189.5M |
| Income Tax | $0 | $0 | $0 | $2.0M | $6.2M | -$15.4M |
| Net Income | -$32.2M | -$69.6M | -$140.0M | $10.9M | $89.2M | $204.8M |
| Diluted EPS | -$1.71 | -$3.13 | -$5.49 | $0.39 | $3.00 | $6.84 |
Krystal Biotech Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $97.8M | $107.1M | $116.4M | $119.2M |
| Net Income | $79.4M | $51.4M | $55.9M | $54.8M |
| Diluted EPS | $2.66 | $1.72 | $1.83 | $1.79 |
Krystal Biotech Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $268.3M | $341.2M | $161.9M | $358.3M | $344.9M | $496.3M |
| Current Assets | $275.1M | $442.3M | $383.8M | $587.9M | $742.0M | $1.02B |
| Total Assets | $310.8M | $626.3M | $558.5M | $818.4M | $1.06B | $1.33B |
| Current Liabilities | $15.5M | $25.7M | $28.8M | $33.1M | $102.0M | $102.9M |
| Total Liabilities | $18.8M | $32.7M | $36.2M | $39.7M | $109.5M | $114.2M |
| Shareholders' Equity | $292.1M | $593.6M | $522.2M | $778.6M | $946.4M | $1.22B |
Krystal Biotech Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$26.1M | -$47.9M | -$100.6M | -$88.8M | $123.4M | $200.9M |
| Cash From Investing | -$11.2M | -$226.8M | -$114.1M | $82.6M | -$163.4M | -$58.4M |
| Cash From Financing | $118.0M | $347.7M | $35.3M | $202.8M | $27.0M | $8.7M |
| Free Cash Flow | -$40.9M | -$116.3M | -$153.5M | -$100.6M | $119.2M | $188.9M |
Figures from Krystal Biotech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Krystal Biotech financials page for every line item.
Krystal Biotech Company Profile
| Ticker | KRYS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Pittsburgh, Pennsylvania |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001711279 |
Frequently Asked Questions
What was Krystal Biotech's revenue in fiscal 2025?
Krystal Biotech (KRYS) reported revenue of $389.1M for fiscal 2025.
What is Krystal Biotech's annual revenue history?
Krystal Biotech's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $50.7M; 2024: $290.5M; 2025: $389.1M.
What was Krystal Biotech's net income in fiscal 2025?
Krystal Biotech reported net income of $204.8M for fiscal 2025.
What was Krystal Biotech's earnings per share (EPS) in fiscal 2025?
Krystal Biotech's diluted EPS was $6.84 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Krystal Biotech generate in fiscal 2025?
Krystal Biotech generated $188.9M of free cash flow in fiscal 2025.
What was Krystal Biotech's revenue last quarter?
In its most recent reported quarter (2026 Q2), Krystal Biotech reported revenue of $119.2M.
How many shares of Krystal Biotech are outstanding?
Krystal Biotech reported a weighted average of 29.5 million basic shares outstanding in 2026 Q2.
What is Krystal Biotech's market cap?
Based on its latest closing price, Krystal Biotech (KRYS) has a market capitalization of about $9.85B.
When does Krystal Biotech's fiscal year end?
Krystal Biotech's fiscal year end, as registered with the SEC, is December 31.
Where is Krystal Biotech headquartered?
Krystal Biotech lists its business address in Pittsburgh, Pennsylvania in its SEC filings.
Krystal Biotech Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →